Latest Distributions News

Dexus has announced a 19.3 cents per security distribution for HY26, aligned with its updated payout policy, alongside robust financial results and a strategic 10% on-market buyback to address valuation gaps.

Elanor Investors Group reported a $24.5 million net loss for the half year to December 2024, grappling with debt covenant breaches and defaults. The group has struck a $125 million recapitalisation agreement with Rockworth Capital Partners to stabilise its balance sheet and pursue growth.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

GLG Corp Ltd reported an 18.7% drop in revenue to USD 54.1 million for the half year ended December 2025, resulting in a net loss amid challenging macroeconomic conditions and tariff pressures. Despite operational efficiencies improving gross margins, the company refrained from declaring an interim dividend.

Future Generation Australia Limited reported robust financial results for 2025, with a 14.1% investment portfolio gain and a raised fully franked dividend, while continuing its commitment to social impact funding for vulnerable children.

Associate Global Partners Limited reported a significantly reduced half-year loss and modest growth in funds under management, underpinned by strong inflows and strategic capital raising.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Jupiter Mines Limited reported a 15.7% rise in profit after tax for HY2026, driven by its stake in the Tshipi manganese mine and a key joint venture deal with Exxaro Resources. The company navigates production challenges and market shifts while preparing for a dividend decision.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Coles Group reported a 2.5% revenue increase to $23.7 billion for the half year ended January 2026, driven by strong supermarket sales, but earnings were weighed down by a $235 million provision linked to a Fair Work Ombudsman ruling. The company declared a fully franked interim dividend of 41 cents per share.